Clinical Trial

Trial Protocol ID USOR 24089_M24-287

Trial Description

A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Vinni Juneja, MD

Disease Types

Sponsor

  • AbbVie

ClinicalTrials.gov NCT ID

  • NCT06428019